A phase 1/2a first-in-human clinical trial evaluating MDX2001, a multi-specific antibody in patients with advanced solid tumor malignancies

A. Minchom[1], K. Culm[2], E. Garmey[3], L. Makris[3] M.Johnson[4], D. Sommerhalder[5], E. Garralda[6], J. Henry[7], M. Yang[2], L. Mei[3], M. Cotreau[3] A.-L. Goenaga[2], D. Burzyn[2], Z.-Y. Yang[2], R. Wei[2], V. Chhaljani[2], J.Mascola[2], G. Nabel[2], and E. Dumbrava[8]

[1]Drug Development Unit, Institute of Cancer Research, London, United Kingdom; [2]ModeX Therapeutics, an OPKO Health Company, Weston, MA, United States; [3]Consultant, ModeX Therapeutics, an OPKO Health Company, Weston, United States; [4]Sarah Cannon Research Institute, Nashville, TN, United States; [5]NEXT Oncology, San Antonio, United States; [6]Vall d'Hebron University Hospital, Barcelona, Spain, [7]Sarah Cannon Research Institute, Denver, CO, United States; [8]The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

European Society for Medical Oncology Congress 2024 - 680TiP

MDX2001 – A Lymphocyte Activation and Survival Enhancement Receptor Antibody (LASER)



- A next generation multispecific antibody activating T cells using signal 1 (CD3) and enhancing survival via signal 2 (CD28) to optimize sustained tumor killing.
- Dual tumor targeting of cMET and TROP2 increases specificity of tumor recognition and mitigates escape resistance that can occur through loss of a single tumor antigen.



- Enhanced T cell survival and proliferation by engaging CD28 in the presence of CD3 activation[1]



CD3/CD28 co-signaling activates Bcl-xL



CD3×CD28 co-signaling markedly increases T cell proliferation

[1]Seung E et al., 2022A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells. Nature, 603, pp 328-334.

MDX-2001-101 Study Design



Study Objectives

Primary	○ Safety and tolerability in patients with advanced solid tumor malignancies ○ Identify a recommended Phase 2 dose ○ Assess the anti-tumor efficacy in patients with selected advanced solid tumor malignancies *(Phase 1b/2)*
Secondary	○ Further characterize anti-tumor efficacy and clinical benefit ○ Characterize pharmacokinetics and immunogenicity ○ Characterize relationship of baseline target protein expression in tumor tissue and clinical benefit
Exploratory	○ Evaluate potential biomarkers in tumor tissue and blood pre- and post-treatment that may predict or correlate with response to MDX2001

Trial Sites in the US, UK and Europe

- MD Anderson Cancer Center
  Ecaterina Dumbrava, MD
  Houston, TX (2024)
- Sarah Cannon Research Institute
  Melissa Johnson, MD
  Nashville, TN (2024)
- NEXT Oncology
  David Sommerhalder ,MD
  San Antonio, TX (2024)
- Sarah Cannon Research Institute
  Jason Henry, MD
  Denver, CO (2024)
- Royal Marsden Hospital
  Anna Minchom, MD
  London, UK (2025)
- NEXT Oncology
  Elana Garralda, MD
  Barcelona, ES (2025)

Clinical Trial Page

A Phase 1/2a, Multicenter, First-in-Human, Open-Label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors

clinicaltrials.gov/study/NCT06239194

Tumor Indication Focus for Phase 1a Dose Escalation

○ Biliary tract cancer	○ Head & neck cancer
○ Breast cancer	○ Hepatocellular cancer
○ Cervical cancer	○ Non-small cell lung cancer
○ Colon or rectal cancer	○ Pancreatic cancer
○ Endometrial cancer	○ Prostate cancer
○ Esophageal cancer	○ Renal cancer
○ Gastric & gastroesophageal junction cancer	○ Thyroid cancer

○ Other histologic tumor types based upon agreement with the sponsor

Key Inclusion Criteria

- Patients must be ≥ 18 years of age
- Histologically or cytologically confirmed diagnosis of metastatic solid tumors
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- All patients should have at least 1 measurable disease per RECIST v1.1. An irradiated lesion can be considered measurable only if progression has been demonstrated on the irradiated lesion.
- Adequate hematologic, hepatic and renal function and appropriate contraceptive use for clinical trial participation.
- Capable of giving signed informed consent

Key Exclusion Criteria

- Any clinically significant cardiac disease
- Unresolved toxicities from previous anticancer therapy
- Prior solid organ or hematologic transplant
- Known untreated, active, or uncontrolled brain metastases
- Known positivity with human immunodeficiency virus (HIV), known active hepatitis B or C, or uncontrolled chronic or ongoing infectious requiring intravenous treatment.
- Receipt of a live-virus vaccination within 28 days of planned treatment start
- Participation in a concurrent clinical study in the treatment period.
- Known hypersensitivity to MDX2001 or any of its ingredients